A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. We are developing verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (“TSLP”), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Preclinical and clinical data to date demonstrate verekitug’s highly potent inhibition of the TSLP receptor, which we believe will translate to a differentiated product profile, including improved clinical outcomes, substantially extended dosing intervals and the potential to treat a broad spectrum of patients.
| Metric | TTM | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 2.8M | - | - |
| Net Income | -123M | -76M | -38M |
| EPS | $10.69 | $-5.58 | $-12.95 |
| Free Cash Flow | 0 | -60M | -38M |
| ROIC | -1802.9% | -16.1% | -34.2% |
| Gross Margin | - | - | - |
| Debt/Equity | 0.00 | - | -0.00 |
| Dividends/Share | $0.00 | - | - |
| Operating Income | -141M | -78M | -40M |
| Operating Margin | -5020.1% | - | - |
| ROE | -32.4% | - | - |
| Shares Outstanding | 54M | 54M | 54M |
| Metric | 2023 | ||
|---|---|---|---|
| Income Statement | |||
| Revenue | N/A | N/A | 2.8M |
| Gross Margin | N/A | N/A | N/A |
| R&D | 32M | 63M | 118M |
| SG&A | 11M | 17M | 25M |
| EBIT | -40M | -78M | -141M |
| Op. Margin | N/A | N/A | -5020.1% |
| Net Income | -38M | -76M | -123M |
| Net Margin | N/A | N/A | -4386.4% |
| Non-Recurring | 0 | 0 | 0 |
| Returns on Capital | |||
| ROIC | -34.2% | -16.1% | N/M |
| ROE | N/A | N/A | -32.4% |
| ROA | -32.6% | -25.5% | -31.4% |
| Cash Flow | |||
| Op. Cash Flow | -38M | -59M | -122M |
| Free Cash Flow | -38M | -60M | 0 |
| Owner Earnings | -41M | -65M | -132M |
| CapEx | 144K | 511K | 0 |
| Maint. CapEx | 60K | 89K | 180K |
| Growth CapEx | 84K | 422K | 0 |
| D&A | 60K | 89K | 180K |
| CapEx/OCF | N/A | N/A | 0.0% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% |
| Stock-Based Comp | 3.3M | 6.0M | 9.9M |
| Debt Repayment | 0 | 0 | 0 |
| Balance Sheet | |||
| Net Debt | -110M | -468M | -372M |
| Cash & Equiv. | 26M | 326M | 372M |
| Long-Term Debt | N/A | N/A | N/A |
| Debt/Equity | -0.00 | N/A | 0.00 |
| Interest Coverage | N/A | N/A | N/A |
| Equity | -123M | N/A | 379M |
| Total Assets | 117M | 482M | 391M |
| Total Liabilities | 9.4M | N/A | 13M |
| Intangibles | N/A | N/A | N/A |
| Retained Earnings | -128M | -191M | -292M |
| Working Capital | 110M | 468M | 377M |
| Current Assets | 117M | 479M | 389M |
| Current Liabilities | 6.5M | 11M | 12M |
| Per Share Data | |||
| EPS | -12.95 | -5.58 | 10.69 |
| Owner EPS | -0.77 | -1.22 | -2.45 |
| Book Value | -2.30 | N/A | 7.01 |
| Cash Flow/Share | -0.71 | -1.10 | -2.27 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | 53.6M | 53.6M | 54.0M |
| Valuation | |||
| P/E Ratio | N/A | N/A | 1.0 |
| P/FCF | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 1.5 |
| Price/Sales | N/A | N/A | 199.6 |
| FCF Yield | N/A | -5.8% | N/A |
| Market Cap | N/A | 1.0B | 559M |
| Avg. Price | N/A | 22.53 | 10.34 |
| Year-End Price | N/A | 19.19 | 10.34 |
Upstream Bio, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Upstream Bio, Inc. (UPB) has a 5-year average return on invested capital (ROIC) of -25.2%. This is below average and may indicate limited pricing power.
Upstream Bio, Inc. (UPB) has a market capitalization of $559M. It is classified as a small-cap stock.
Upstream Bio, Inc. (UPB) does not currently pay a regular dividend.
Upstream Bio, Inc. (UPB) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Upstream Bio, Inc. (UPB) generated $-60 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Upstream Bio, Inc. (UPB) reported earnings per share (EPS) of $-5.58 in its most recent fiscal year.
The Ledger Terminal provides 2 years of financial data for Upstream Bio, Inc. (UPB), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.